AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

F&P Healthcare FY25 guidance to be in the spotlight
Markets

F&P Healthcare FY25 guidance to be in the spotlight

Analysts are upbeat about FY25 revenue potential. 

Rua Gold gets exploration green light
Markets

Rua Gold gets exploration green light

The company hopes to begin exploration drilling in Coromandel by the year's end.

The Madness of Crowds…
Markets

Simon Robertson: The Madness of Crowds…

It's a lot of fun to go down rabbit holes and get your head around new businesses. 

Simon Robertson 25 May 2024
Dimming faith in interest rate cuts give NZ market the jitters
Markets Market close

Dimming faith in interest rate cuts give NZ market the jitters

Small slip in NZ follows sharp fall on Wall Street.

Graham Skellern 24 May 2024